全球新冠檢測產品銷售額度增加 雅培第一季度營收和利潤雙雙增長
格隆匯4月20日丨雅培(ABT.US)公佈第一季度業績,公司實現每股收益1.37美元,高於上年同期的1美元;調整後每股收益為1.73美元,分析師預計為1.47美元。淨利潤為24.5億美元,高於上年同期的17.9億美元;當季營收從12個月前的104.6億美元升至119億美元;分析師預計營收為109.9億美元。按照業務劃分,營養品銷售額下降7%至18.9億美元;診斷產品銷售額增長32%至52.9億美元;醫療設備收入增長7.4%,至35.7億美元。其中全球新冠檢測相關銷售額為33億美元,高於去年同期的21.9億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.